World journal of virology · 2025
Cytomegalovirus reactivation risk after autologous hematopoietic stem cell transplantation: Results of a Tunisian study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ben Moussa Mouna Louiza, Chelbi Yasmine, Kharrat Rachid, Berred Rabeb, Ben Lakhal Raihane, Hamdoun Manel, Bahri Olfa
Аннотация
BACKGROUND: Cytomegalovirus (CMV) reactivation is a potentially severe complication in immunocompromised patients, yet its incidence and impact in recipients of autologous hematopoietic stem cell transplantation (AHSCT) remain insufficiently documented.
AIM: To assess the frequency, timing, and outcomes of CMV reactivation in patients undergoing AHSCT at Aziza Othmana Hospital.
METHODS: We conducted a retrospective descriptive study of all patients who underwent AHSCT between January 2022 and December 2024 and had at least one post-transplant plasma viral load (VL) assessment. CMV VL was quantified by real-time polymerase chain reaction using TaqMan probes (GeneProof®) with a sensitivity threshold of 150 IU/mL.
RESULTS: Among 277 AHSCT recipients, 17 (6.1%) experienced CMV reactivation. Their median age was 43 years, with a sex ratio of 0.46 (male/female). Underlying diseases included large B-cell lymphoma (n = 5), multiple myeloma (n = 3), and Hodgkin's lymphoma (n = 4). The median time to reactivation was 26 days post-transplant (11 days after neutrophil recovery). Median peak VL was 1325 IU/mL (range: 150-641000 IU/mL). Six patients required antiviral therapy (median peak VL: 30150 IU/mL), while 11 had spontaneous resolution (median peak VL: 1320 IU/mL). Two patients died in the context of CMV reactivation.
CONCLUSION: CMV reactivation occurs in a noteworthy proportion of AHSCT recipients and may lead to severe outcomes. Routine VL monitoring in the early post-transplant period is crucial, and preemptive therapy should be initiated once clinically relevant VL thresholds are reached to prevent progression to CMV disease and associated mortality.
AIM: To assess the frequency, timing, and outcomes of CMV reactivation in patients undergoing AHSCT at Aziza Othmana Hospital.
METHODS: We conducted a retrospective descriptive study of all patients who underwent AHSCT between January 2022 and December 2024 and had at least one post-transplant plasma viral load (VL) assessment. CMV VL was quantified by real-time polymerase chain reaction using TaqMan probes (GeneProof®) with a sensitivity threshold of 150 IU/mL.
RESULTS: Among 277 AHSCT recipients, 17 (6.1%) experienced CMV reactivation. Their median age was 43 years, with a sex ratio of 0.46 (male/female). Underlying diseases included large B-cell lymphoma (n = 5), multiple myeloma (n = 3), and Hodgkin's lymphoma (n = 4). The median time to reactivation was 26 days post-transplant (11 days after neutrophil recovery). Median peak VL was 1325 IU/mL (range: 150-641000 IU/mL). Six patients required antiviral therapy (median peak VL: 30150 IU/mL), while 11 had spontaneous resolution (median peak VL: 1320 IU/mL). Two patients died in the context of CMV reactivation.
CONCLUSION: CMV reactivation occurs in a noteworthy proportion of AHSCT recipients and may lead to severe outcomes. Routine VL monitoring in the early post-transplant period is crucial, and preemptive therapy should be initiated once clinically relevant VL thresholds are reached to prevent progression to CMV disease and associated mortality.